Amlexanox vs Survodutide
A side-by-side research comparison of Amlexanox and Survodutide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Amlexanox | Survodutide |
|---|---|---|
| Full name | Amlexanox (TBK1/IKKε Inhibitor) | Survodutide (Dual GLP-1/Glucagon Agonist) |
| Category | Weight Management | Weight Management |
| Status | Research / Off-label | Phase 3 Clinical Trial |
| Mechanism | Inhibits IKKε and TBK1 kinases that are upregulated in obesity, which normally suppress energy expenditure. Blocking these kinases restores thermogenesis and improves insulin sensitivity. | Activates GLP-1 receptors to reduce appetite while glucagon receptor activation increases hepatic fat oxidation, energy expenditure, and amino acid catabolism. |
| Molecular weight | 298.29 Da | 4,500 Da (approximate) |
| Half-life | ~3-4 hours | 5-7 days |
| Bioavailability | ~70% oral | High (SubQ) |
| Typical dose | 25-100 mg | 0.6-6.0 mg |
| Frequency | 3x daily | Once weekly |
| Route | Oral tablet | Subcutaneous |
Amlexanox reported benefits
- Increased energy expenditure
- Improved insulin sensitivity
- Weight loss
- Reduced inflammation
- Metabolic reset
Survodutide reported benefits
- Significant weight loss (up to 19%)
- Liver fat reduction
- Increased energy expenditure
- MASH resolution potential
- Improved lipid profile
Related comparisons
Research and educational reference only. Not medical advice.